Qiji Investment
齐济投资
Qiji Investment (齐济投资) is a Chinese investment firm that elsewhere's corpus shows mainly as a co-investor in healthcare deals. In August 2025 it followed on in Zenitar's nearly RMB 400 million Series B+ round, led by Qiming Venture Partners alongside Gaorong, Jifeng Capital, 5Y Capital and Zhongyuan Investment ; earlier, in late 2023, it joined the angel-plus round of Shenzhen-based WeLing Medical, a company developing a fully implantable medical-grade brain-computer interface, in a round led by Gaorong Capital . Both appearances point to a focus on biopharma and frontier medical technology, but the corpus contains no dedicated coverage of the fund itself — its founding, team and fund size are not documented here, so a fuller profile isn't possible from this material.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Zai Ling Bio Completes Nearly RMB 400 Million Series B+ Round
Accelerating the buildout of an innovative drug pipeline built on differentiated molecular scaffolds and novel targets, with a commitment to addressing unmet clinical needs.
Zenitar Closes Nearly RMB 400 Million Series B+ Round, Multiple Global First-in-Class Drugs Enter Pivotal Clinical Trials
Structural Biology and AI-Driven Innovative Drug Discovery and Development
Zenitar Raises Nearly 400 Million Yuan in B+ Round Led by Qiming Venture Partners
Zenitar is a structure-based biology and AI-driven innovative drug R&D company, focused on unmet clinical needs in major therapeutic areas including oncology, autoimmune diseases, inflammation, and neurological disorders. The company is dedicated to discovering, developing, and commercializing first-in-class and best-in-class innovative medicines.
WeLing Medical Completes Angel Plus Round to Advance Fully Implantable Medical-Grade Brain-Computer Interface System
Accelerating the clinical translation of brain-computer interface technology.
